Navigation Links
TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan
Date:3/10/2015

TAIPEI, March 10, 2015 /PRNewswire/ -- TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received the designation of Rare Disease Drug by Taiwan FDA for use of AC-203 to treat Epidermolysis Bullosa Simplex (EBS), and is eligible for applying for coverage under National Health Insurance Administration (NHIA).  TWi Biotechnology has developed proprietary formulations to be used topically for the indication of EBS and will plan for further development and product launch according to the designation.

"We are very pleased with the TFDA's approval of the rare disease drug designation for treating epidermolysis bullosa simplex.  This is a major milestone of AC-203, which has obtained the orphan drug designation from U.S. FDA just several months ago.  In addition, this fulfills the mission of our new drug business for developing proprietary formulations and meeting unmet medical needs," said Dr. Calvin C. Chen, President of TWi Biotechnology.  "Epidermolysis Bullosa, or EB, is a very rare genetic connective tissue disorder that affects several hundred of children in Taiwan suffering from this disease; patients with EB are known as 'Bubble Dragon Children' in Taiwan or 'Butterfly Children' in the United States due to their extremely fragile skin that blisters and tears from friction or trauma. We hope this rare disease drug designation can not only help the patients in Taiwan but also speed the development of topical AC-203 in other places of the world.  Current treatments for EBS focus on relief of symptoms such as itching and pain, and wound care to prevent infection, which include expensive treatments such as artificial skin and may require frequent visits to hospitals.  In contrast, the topical formulation of AC-203 is developed to prevent or reduce the blisters that, if successful, may alleviate the suffering of the patients and their families from this deliberating disease."

About AC-203
AC-203 is the topical formulation of a first-in-class small molecule known as AC-201 which has shown the ability to inhibit the production and activity of caspase-1 and the cytokine Interleukin-1Beta (IL-1Beta), and to down-regulate IL-1Beta receptors. Inhibition of IL-1Beta signaling has been demonstrated to be effective in treating a variety of diseases including arthritis, gout, and diabetes mellitus (DM). The active ingredient of AC-201 has been approved for treating patients with chronic rheumatic diseases in France and subsequently in other EU and Middle Eastern countries such as Spain and Italy since mid-1990.

TWi Biotechnology holds two US INDs for AC-201 – one for controlling blood glucose in patients with type II diabetes and the other for treating gout in patients undertaking urate-lowering therapy. In addition to the good safety record of its active ingredient used in treating another chronic disease, AC-201 has undergone testing in several human clinical trials including 3 phase II trials for up to 6 months treatment period with a satisfactory safety profile demonstrated.

About Epidermolysis Bullosa (EB)
EB is caused by mutations in the DNA code that make up genes.  Genes are responsible for making and expressing proteins.  EB can result from one genetic mutation in any one of the 18 genes that have been found to cause the disorder.  These mutations, or errors in the genetic code, may not allow the affected gene to produce a specific protein, or it may result in the incorrect formation of that protein.  Either way, the mutation disrupts the correct function of the protein, thus resulting in extremely fragile skin, and other manifestations of EB including: anemia, cardiomyopathy, syndactyly (fusion of the fingers and toes), renal insufficiency, dysphagia (difficulty swallowing), malnourishment, cancer, constipation, osteoporosis, muscular dystrophy and pyloric atresia.

About TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a fully owned subsidiary of TWi Pharmaceuticals, Inc., is a leading clinical stage biopharmaceutical company based in Taipei, Taiwan, specializing in the development of innovative new drugs for unmet medical needs, especially in the diseases associated with innate immunity. The company is building its product pipeline through in-licensing and internal research. TWi Biotechnology's product development pipeline includes three drug candidates for treating type II diabetes, retinopathy, arthritis, and immunodermatology diseases.

Contact :
Eric Lin 
Tel: +886-2-2657-3350 #407
Email: eric.lin@twipharma.com


'/>"/>
SOURCE TWi Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Sony Biotechnology Inc.s New Technology for Science Provides Researchers Results in Color
2. Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
3. Platine Pharma Services et Indicia Biotechnology se rapprochent pour renforcer leur leadership en immunomonitoring
4. ResearchMoz.us: Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
5. The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
6. Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments
7. TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States
8. Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
9. Goodwin Biotechnology Announces the Appointment of SooYoung S. Lee, PhD as Chief Operating Officer
10. NextSource Biotechnology Launches New Strategic Approach to Mitigate Slow-Downs in Manufacturing of Matured Medications in High Demand
11. Cytos Biotechnology Ltd Announces the Completion of Patient Enrolment in the On-going Phase 2b Study of CYT003 for the Treatment of Allergic Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/11/2019)... ... November 11, 2019 , ... Over 60 schools in the northwest panhandle ... The program is designed to provide virtual mental health care to more than 35,000 ... region in October of 2018 [1]. , “This initiative by the state of Florida,” ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... have a major impact in the oncology field. While these approaches have ... overcome. Among these, defining valuable and adapted combination protocols, predicting responders to ...
(Date:11/9/2019)... , ... November 08, 2019 , ... ... Pulmonary Hypertension Association (PHA) sets aside a day to help raise awareness and ... thromboembolic pulmonary hypertension (CTEPH). Unlike some forms of PH, CTEPH has several treatment ...
Breaking Medicine Technology:
(Date:11/14/2019)... DIEGO (PRWEB) , ... November 14, 2019 , ... ... three categories of HREI magazine’s annual, national awards program. The three projects include ... a Federally Qualified Health Center in El Centro, Calif. that provides medical care ...
(Date:11/12/2019)... ... November 12, 2019 , ... Each year, RESOLVE ... truly impacted those diagnosed with infertility. This year, Academy of Adoption and Assisted ... presented at the Night of Hope Gala in New York City on November ...
(Date:11/12/2019)... ... November 12, 2019 , ... InteliChart, the leader in ... Tidewater Physicians Multispecialty Group (TPMG), a network of 220 providers across 85 ... platform to deliver enhanced patient experience and overall engagement to their patients. ...
(Date:11/12/2019)... MESA, Calif. (PRWEB) , ... November 12, 2019 ... ... professional certification, licensing, and compliance management, today announced the release of new features ... feel of Certemy’s platform interface and emails to match their physical brand attributes. ...
(Date:11/11/2019)... ... November 11, 2019 , ... Smile Brands Inc., one ... the United States, today announced the grand opening of another affiliated Bright ... enjoy convenient hours, comfortable offices and full-service care at the new location. The ...
Breaking Medicine News(10 mins):